newsfilter
← Latest News
ACCESS Newswire·

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform